🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD. 🎧 Available now on Spotify and Apple Podcasts, don’t miss it! 🔗 Spotify: https://bit.ly/43DbKPR 🔗 Apple: https://apple.co/3Jmk5Ax

🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD. 🎧 Available now on Spotify and Apple Podcasts, don’t miss it! 🔗 Spotify: https://bit.ly/43DbKPR 🔗 Apple: https://apple.co/3Jmk5Ax

🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD. 🎧 Available now on Spotify and Apple Podcasts, don’t miss it! 🔗 Spotify: https://bit.ly/43DbKPR 🔗 Apple: https://apple.co/3Jmk5Ax

🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD. 🎧 Available now on Spotify and Apple Podcasts, don’t miss it! 🔗 Spotify: https://bit.ly/43DbKPR 🔗 Apple: https://apple.co/3Jmk5Ax

Quality of life in FA isn’t just about walking or speech—it’s also about mood, behavior and functional participation. Our care models must keep up. Read more: https://bit.ly/3J6JKgp #PatientCare #RareNeurologicDisorders

For clinicians: seeing “AI counseling” as a tool, not a substitute. Ensure human supervision, cultural competence checks, and built-in crisis safeguards before deployment. Read more: https://bit.ly/49jjERN #ClinicalPractice #TechIntegration

For mental-health program leaders: the evidence base for aripiprazole monohydrate LAI is maturing—now is a good time to revisit your protocols for selecting, initiating and following patients on LAIs. Read more: https://bit.ly/3JhyIoC  #ServiceDesign #PsychiatricCare

The research agenda must evolve: Which patient subgroups, treatment settings or infusion regimens might still show benefit? And how should outcomes be tracked over time? Read more: https://bit.ly/4qvn7To  #Research #InnovationInCare

Clinicians: when cognitive decline shows up, don’t only check hypertension. Ask: “Has the patient’s blood pressure dropped below their norm lately?” It could be a key clue. Read more: https://bit.ly/4hEktH5 #PatientCare #Assessment

The brain’s “fuel” is blood flow. Cut it off (even partially) and you trigger oxidative stress, calcium influx, cell death—starting within minutes.  https://bit.ly/4hEktH5 #PerfusionMatters #Neurobiology

Accountability gap: Unlike licensed human therapists, AI counselors are not certified, regulated or bound by professional boards — yet they’re engaging in therapeutic roles. That matters. Read more: https://bit.ly/49jjERN #Regulation #AIInHealth

Interdisciplinary coordination (neurology + psychiatry + long-term-care nursing) is not optional—it’s essential when behavioral symptoms emerge in hereditary ataxia settings. Read more: https://bit.ly/3J6JKgp #LongTermCare #TeamBasedCare

Embedding LAIs into treatment workflows: beyond prescribing, services must include patient education, monitoring intervals and adherence support to fully leverage the advantages of aripiprazole LAI. Read more: https://bit.ly/3JhyIoC #MentalHealthServices #Implementation

For programs offering off-label ketamine infusions: current evidence suggests modest benefit at best when used as an adjunct in inpatient settings. Managing expectations is essential. Read more: https://bit.ly/4qvn7To  #HealthServices #PatientCare

Hypotension + another insult (hypoxia, anemia, TBI) = higher risk for cognitive/neurological damage. It’s the combo that compounds the harm.  https://bit.ly/4hEktH5 #CriticalCare #BrainFlow

A new inpatient trial of repeated ketamine infusions found no significant advantage over an active psychoactive control in reducing depressive symptoms. Read more: https://bit.ly/4qvn7To  #Psychiatry #Depression

The pharmacologic balance in FA: Treating psychiatric symptoms without worsening motor/neurologic function is complex—but possible, as shown in a recent long-term care case. Read more: https://bit.ly/3J6JKgp #Psychopharmacology #Neurology

Initiation planning matters: variability in metabolism (CYP2D6/CYP3A4), drug-interactions and patient history must guide LAI selection and management. Read more: https://bit.ly/3JhyIoC #ClinicalPractice #PrecisionMedicine

One hour. Two experts. 1.25 CME credits. All designed to help you deliver better DMD care. 🗓 October 30 | Live Virtual CME 🔗 Register → https://cmeinstitute.com/live-dmd-2025/

Crisis-handling matters: Chatbots that don’t reliably offer emergency resources when suicidal ideation arises are operating outside the ethics we expect in therapy. Read more: https://bit.ly/49jjERN  #PatientSafety #AIMentalHealth

When you hear “low blood pressure,” think: is this low *for this patient? A drop from their baseline may hurt cognition even if it’s within “normal” range for most.  Read more: https://bit.ly/4hEktH5 #ClinicalInsight #Neurology

More than generative text: When AI “counselors” overlook cultural/familial context (e.g., advising independence while ignoring guilt tied to cultural norms) — that’s a red flag. Read more: https://bit.ly/49jjERN #DigitalTherapy #ClinicalInsight

In FA, neuropsychiatric symptoms are under-recognized as part of the disease spectrum. Early detection and integrated care can make a major difference. Read more: https://bit.ly/3J6JKgp #RareDisease #BehavioralHealth

The once-every-two-month ready-to-use aripiprazole LAI is now emphasized for its potential to improve convenience and adherence—especially in populations where daily medication is challenging. Read more: https://bit.ly/3JhyIoC #Adherence #Psychopharmacology

Blinding issues matter: in the trial most participants and raters accurately guessed who received ketamine — a factor that may inflate perceived benefits.  Read more: https://bit.ly/4qvn7To #ClinicalTrialDesign #Psychopharmacology

New consensus panel report highlights that aripiprazole monohydrate LAIs offer more stable pharmacokinetics than daily oral dosing—potentially better aligning treatment with long-term needs in schizophrenia & bipolar I. Read more: https://bit.ly/47sc9p8 #Psychiatry #LAI

A new study flags major ethical gaps in AI-therapy chatbots: poor contextual awareness, deceptive empathy and weak crisis handling. Read more: https://bit.ly/49jjERN #MentalHealth #AIethics

One hour. Two experts. 1.25 CME credits. All designed to help you deliver better DMD care. 🗓 October 30 | Live Virtual CME 🔗 Register → https://cmeinstitute.com/live-dmd-2025/

Despite promising early data, when layered onto standard inpatient care, ketamine infusions did not yield better outcomes in mood, cognition or quality of life in a recent study. Read more: https://bit.ly/4qvn7To  #EvidenceBased #MentalHealth

Patients with Friedreich’s ataxia may display significant neuropsychiatric symptoms—including depression, refusal of care/food and aggression—not just motor decline. Read more: https://bit.ly/3J6JKgp  #FriedreichsAtaxia #Neuropsychiatry

Low BP isn’t always benign. A new study shows both absolute and relative hypotension can impair brain function via reduced perfusion → neuronal stress → potential damage. Read more: https://bit.ly/4hEktH5 #BrainHealth #Hypotension

New research suggests that mixing tobacco with cannabis might amplify the brain changes linked to both. 🧠

Rare presentations like incubus syndrome remind us that delusions are shaped by context—and must be approached with diagnostic rigor and cultural awareness. Full case report: 🔗 https://www.psychiatrist.com/pcc/incubus-syndrome-man-alcohol-dependence/ #Psychiatry #CulturalCompetency #CaseStudy

Social cognition is a promising target for early psychosis care. Integrating it into treatment may improve long-term outcomes. Read the full research: 🔗 https://www.psychiatrist.com/news/how-social-thinking-shapes-recovery-in-early-schizophrenia/

Clozapine + ECT is often used in treatment-resistant schizophrenia. But clinicians must remain alert for rare complications like NMS. This case illustrates how to intervene quickly and safely. 🔗 https://bit.ly/4n9aASR #Psychiatry #Schizophrenia #ClozapineCare

A new poll has shown that the majority of Americans are significantly worried about their health care costs increasing

Somatic delusions are rare—but underrecognized. This article outlines clinical signs, diagnostic pearls, and treatment options. Essential reading for psychiatric and general medical providers. 🔗 https://bit.ly/43rZJMG #Psychiatry #SomaticDelusions #MedicalPsychiatry

Mental health in the U.S. stands at a crossroads. Will the next era be one of renewed innovation—or continued decline? Read the full analysis at Psychiatrist.com: https://www.psychiatrist.com/news/mental-health-progress-stalls-at-a-crossroads/ #MentalHealthResearch #Psychiatry

Get the evidence-based guidance you need to keep pace. Join leading experts for Next-Generation DMD Care, a live CME on October 30. https://cmeinstitute.com/live-dmd-2025/

If it’s in the news—or about to be—it’s in your inbox. Stay ahead in clinical psychiatry. 🧠 Sign up for free: https://www.psychiatrist.com/membership/ #Psychiatry #ClinicalNews #MedicalUpdates

Too many tabs, not enough time? A free Essential Membership gives you curated psychiatry updates without the search. 📬 https://www.psychiatrist.com/membership/

Why does NMS develop in clozapine patients—despite its atypical pharmacologic profile? This case prompts new questions for clinicians and researchers alike. 🔗 https://www.psychiatrist.com/pcc/neuroleptic-malignant-syndrome-clozapine-ect-schizophrenia/

Study takeaway: Patients with stronger social cognitive skills at baseline were more likely to achieve real-world functional recovery. #EarlyIntervention #MentalHealth 🔗 https://www.psychiatrist.com/news/how-social-thinking-shapes-recovery-in-early-schizophrenia/

Progress is not inevitable. Without renewed investment in prevention, early intervention, and access to treatment, the next decade may see further regression. 🔗 https://www.psychiatrist.com/news/mental-health-progress-stalls-at-a-crossroads/

Comorbid alcohol dependence complicates presentation: • Increased vulnerability to psychosis • Sleep disruption • Potential for withdrawal-related symptoms This case outlines how clinicians navigated those layers. 🔗 https://www.psychiatrist.com/pcc/incubus-syndrome-man-alcohol-dependence/

Case-based insight: A patient convinced worms were in their skin underwent unnecessary testing before the psychiatric etiology was recognized. Early psychiatric consultation could have changed the course. 📖 https://www.psychiatrist.com/pcc/somatic-delusions-an-approach-to-diagnosis-and-treatment/

Clinical decision-making in this case: ✔️ Immediate cessation of ECT ✔️ Hospitalization ✔️ Medication management ✔️ Gradual re-initiation of psychiatric treatment 🔗 https://www.psychiatrist.com/pcc/neuroleptic-malignant-syndrome-clozapine-ect-schizophrenia/

Why wait to find out what’s new in psychiatry? Get highlights, peer-reviewed content, and CME opportunities—sent directly to your email. 🖱️ Free sign-up: https://www.psychiatrist.com/membership/

The challenge: Distinguishing cultural or spiritual interpretation from true delusional intensity. This case required careful differential diagnosis and clinical sensitivity. 📖 https://www.psychiatrist.com/pcc/incubus-syndrome-man-alcohol-dependence/

Get the evidence-based guidance you need to keep pace. Join leading experts for Next-Generation DMD Care, a live CME on October 30. https://cmeinstitute.com/live-dmd-2025/